The Evolving Landscape of Anemia in MDS & MPN: Clinical Updates and Best Practices
Released On
September 24, 2025
Expires On
September 23, 2026
Media Type
Internet
Completion Time
4.0 hours
Specialty
Hematology-Oncology
Topic(s)
Anemia, Leukemia, Oncology, Myeloproliferative neoplasms, Myelodysplastic syndromes
Providers/Grant Support
This activity is provided by SOHO and MLI
This educational activity is supported by independent medical education grants from Bristol Myers Squibb, Geron, and GSK.
Credit Available
- AMA — maximum of 4.0 AMA PRA Category 1 Credits™
- ABIM MOC — up to 4.0 MOC points
- NCPD — 4.0 Nursing continuing professional development contact Hours
- Physician Associates — 4.0 AAPA Category 1 CME credits
- CPE — 4.0 contact Hours
- EBAH — maximum of 4.0 EBAH CME-CPD credits
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
Hematology/oncology physicians, physician associates (PAs), nurse practitioners (NPs), nurses, pharmacists, residents, fellows, and other members of the healthcare team.
Program Overview
The Evolving Landscape of Anemia in MDS & MPN: Clinical Updates and Best Practices targets global hematology/oncology clinicians who manage patients with MDS and MPN experiencing anemia. Guided by esteemed co-chairs, Guillermo Garcia-Manero, MD, and John Mascarenhas, MD, the workshop will feature a multidisciplinary panel, including experts in hematology/oncology, pathology, cardiology, and supportive care. Through dynamic case studies, interactive polling, and engaging interprofessional discussions, participants will gain actionable insights on:
- Diagnosing and prognosing anemia in MDS and MPN
- Managing anemia to optimize patient quality of life (QoL)
- Navigating the evolving role of the multidisciplinary care team
This evidence-based, case-driven format empowers clinicians to apply emerging clinical updates and best practices, fostering collaboration and improving outcomes for patients with MDS and MPN. Dinner and an open-mic opportunity to ask questions will be provided.
This activity is derived from a presession workshop symposium at the Society of Hematologic Oncology 2025 Annual Meeting, originally held on September 2, 2025.
Learning Objectives
After completing this activity, the participant should be better able to:
- Describe the impact of anemia on quality of life in patients with myelodysplastic syndromes (MDS) and patients with myeloproliferative neoplasms (MPNs)
- Employ the diagnostic criteria for anemia associated with MDS and MPNs, using clinical, morphological, and genomic data to enhance diagnostic accuracy
- Incorporate risk stratification tools and their applications in guiding treatment decisions for patients with MDS and MPNs who experience anemia
- Evaluate the latest efficacy and safety data surrounding novel and emerging therapies for anemia in MDS and MPNs
- Apply evidence-based approaches for managing anemia in MDS and MPNs, considering patient-specific factors and treatment goals
- Create strategies for effective multidisciplinary collaboration to optimize patient care and address both physical and psychosocial burdens of anemia in MDS and MPNs
Agenda
- The Burden of Anemia in MDS and MPN
- Expert Roundtable: Multidisciplinary Care
- Diagnostic and Prognostic Challenges in Anemia Associated with MDS and MPNs
- Game-Changing Therapies and Personalized Anemia Management: LR-MDS
- Game-Changing Therapies and Personalized Anemia Management: MPN
Faculty
Guillermo Garcia-Manero, MD
Chair Ad Interim, Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX, USA
John Mascarenhas, MD
Director, Center of Excellence in Blood Cancers and Myeloid Disorders
Professor of Medicine
Icahn School of Medicine
Mount Sinai Medical Center
New York, NY, USA
Prithviraj Bose, MD
Professor, Department of Leukemia
Co-Leader, Section of Myeloproliferative Neoplasms
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, TX, USA
Amy E. DeZern, MD, MHS
Professor of Oncology
Vice Chair for Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, MD, USA
Aaron T. Gerds, MD, MS
Associate Professor of Medicine, Cleveland Clinic
Learner College of Medicine of Case Western University
Medical Director, Case Comprehensive Cancer Center Clinical Research Office
Deputy Director for Clinical Research, Cleveland Clinic Taussig Cancer Institute
Cleveland, OH, USA
Rami Komrokji, MD
Section Head - Leukemia & MDS
Vice Chair
H. Lee Moffit Cancer Center
Tampa, FL, USA
Sanam Loghavi, MD
Associate Professor
Department of Hematopathology
MD Anderson Cancer Center
Houston, TX, USA
Anju Nohria, MD, MS
Associate Professor in Medicine
Cardiovascular Division
Brigham and Women's Hospital
Harvard Medical School
Director, Cardio-Oncology Program
Dana-Farber Brigham Cancer Center
Boston, MA, USA
Siram Yennu, MD, MS, FAAHPM
Professor
Department of Palliative Care and Rehabilitation Medicine
MD Anderson Cancer Center
Houston, TX, USA
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute Inc and The Society of Hematologic Oncology. Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute Inc (MLI) designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
For Physicians requesting ABIM MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number and DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
EBAH
Medical Learning Institute Inc is an accredited CME-CPD provider by the European Board for Accreditation in Hematology (EBAH). This educational activity has been accredited for a maximum number of 4.0 EBAH CME-CPD credits. Each participant should only collect credits for time that she/he actually spent in the educational activity.
For EBAH Credit, please provide your EBAH personal account number.
ECMEC
The European Union of Medical Specialists-European Accreditation Council for Continuing Medical Education (UEMS-EACCME®) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit(s)™ into European CME credit (ECMEC®) should contact the UEMS (www.uems.eu).
PAs
Medical Learning Institute Inc has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 4.0 AAPA Category 1 CME credits. Approval is valid until September 23, 2026. PAs should only claim credit commensurate with the extent of their participation.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 4.0 contact hours.
Pharmacy
Medical Learning Institute Inc designates this application-based continuing education activity for 4.0 contact hours (0.4 CEUs) of the Accreditation Council for Pharmacy Education.
UAN: JA0007322-9999-25-042-H01-P
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, view your participation record at the NABP website: https://nabp.pharmacy/
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 4.0 Interprofessional Continuing Education (IPCE) credits for learning and change.
Disclosures of Conflicts of Interest
Medical Learning Institute Inc and The Society of Hematologic Oncology are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Co- Chair/Planner/Presenter
Guillermo Garcia-Manero, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor/Speakers’ Bureau: Ascentage, Bristol Myers Squibb, Curis, Keros, Servier, Taiho
Research Funding/Support: AbbVie, Ascentage, Astex, Bristol Myers Squibb, Chordia, Curis, Genentech, Novartis, Rigel, Servier, Taiho
Co- Chair/Planner/Presenter
John Mascarenhas, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor/Speakers’ Bureau: AbbVie, Bristol Myers Squibb, Disc, Geron, GlaxoSmithKline, Incyte, Italfarmaco SpA, Kartos, Karyopharm, Keros, Merck, MorphoSys, Novartis, PharmaEssentia, Roche, Sobi, Sumitomo
Research Funding/Support: AbbVie, Bristol Myers Squibb, Disc, Geron, Incyte, Italfarmaco SpA, Kartos, Karyopharm, MorphoSys, Novartis, PharmaEssentia, Sobi
Planner/Presenter
Prithviraj Bose, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor/Speakers’ Bureau: AbbVie (ended), Blueprint, Bristol Myers Squibb, CTI (now Sobi), Cogent, Disc, Geron, GlaxoSmithKline, Incyte, Ionis, Jubilant (ended), Karyopharm, Keros (now Takeda), Morphic (ended), MorphoSys (now Novartis), Novartis, Ono (ended), Pharma Essentia, RayThera, Sumitomo
Research Funding/Support: Ajax, Blueprint, Bristol Myers Squibb, Cogent, CTI (now Sobi/ended), Disc, Geron, Incyte, Ionis, Janssen (ended), Kartos, Karyopharm, MorphoSys (now Novartis), Sumitomo, Telios (ended)
Honoraria for educational activities: Aptitude Health; Clinical Care Options; Curio Science, a Vaniam Group Company; Medscape; MJH Life Sciences; PeerView, Practice Point CME; Research to Practice.
Planner/Presenter
Matteo Della Porta, MD, has no relevant financial relationships with ineligible companies to disclose for this educational activity.
Planner/Presenter
Amy E. DeZern, MD, MHS, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor/Speakers’ Bureau: Bristol Myers Squibb, Keros, Servier
Planner/Presenter
Aaron T. Gerds, MD, MS,, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor/Speakers’ Bureau: AstraZeneca (ended), Disc Medicine (ended), Kartos (ended), Keros (ended), Novartis (ended), PharmaEssentia (ended), Rain Oncology (ended)
Honoraria for educational activities (all have ended): ASH, CEC, Eisenhower Institute, MJH
Planner/Presenter
Rami Komrokji, MD, has no relevant financial relationships with ineligible companies to disclose for this educational activity.
Planner/Presenter
Sanam Loghavi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor/Speakers’ Bureau (all have ended): AbbVie, Arima, Bristol Myers Squibb, Caris, Daiichi Sankyo, Kura, QIAGEN, Recordati, Servier, Stemline, Syndax, Tempus AI
Research Funding/Support: Amgen, Astellas (ended)
Stock Shares: AbbVie
Honoraria for educational activities (all have ended): Binaytara Foundation, Mashup Media, MD Education, Medscape, OncLive, VJHemOnc
Planner/Presenter
Anju Nohria, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant: AltaThera (ended), AstraZeneca, Regeneron (ended), Takeda Oncology
Research Funding/Support: Amgen (ended), Bristol Myers Squibb
Other: Editor for the Journal of the American College of Cardiology and receive compensation from the American College of Cardiology
Planner/Presenter
Francesca Palandri, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor/Speakers’ Bureau: AbbVie, AOP, Bristol Myers Squibb, Constellation-MorphoSys, GlaxoSmithKline, Incyte, Kartos-Telios, Novartis, Sierra Oncology, Sobi
Planner/Presenter
Valeria Santini, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor/Speakers’ Bureau: AbbVie, Ascentage, Bristol Myers Squibb/Celgene, CTI, Curis (ended), Geron, GlaxoSmithKline, Jazz, Keros, Novartis, Menarini (ended), Servier, CTI (ended), Syros
Research Funding/Support: Bristol Myers Squibb/Celgene (ended)
Planner/Presenter
Scott Ulmer, MD, has no relevant financial relationships with ineligible companies to disclose for this educational activity.
Planner/Presenter
Siram Yennu, MD, MS, FAAHPM, has no relevant financial relationships with ineligible companies to disclose for this educational activity.
Patient Voice
Sheldon Wayman has no relevant financial relationships with ineligible companies to disclose for this educational activity.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute Inc, the accredited provider, and The Society of Hematologic Oncology, the joint provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Instructions for Participation and Credit
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute Inc.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact MLI at [email protected].
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
About This Activity
Medical Learning Institute Inc and The Society of Hematologic Oncology are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc, and The Society of Hematologic Oncology, or any of its partners, providers, and/or supporters.
Copyright © 2025 Medical Learning Institute Inc. All Rights Reserved
Contact Information
If you have questions regarding your certificate, please contact MLI at [email protected].